JP2024511316A5 - - Google Patents
Info
- Publication number
- JP2024511316A5 JP2024511316A5 JP2023554809A JP2023554809A JP2024511316A5 JP 2024511316 A5 JP2024511316 A5 JP 2024511316A5 JP 2023554809 A JP2023554809 A JP 2023554809A JP 2023554809 A JP2023554809 A JP 2023554809A JP 2024511316 A5 JP2024511316 A5 JP 2024511316A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- amino acid
- domain
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163159051P | 2021-03-10 | 2021-03-10 | |
| US63/159,051 | 2021-03-10 | ||
| US202163227149P | 2021-07-29 | 2021-07-29 | |
| US63/227,149 | 2021-07-29 | ||
| PCT/US2022/019570 WO2022192411A1 (en) | 2021-03-10 | 2022-03-09 | Actrii-alk4 antagonists and methods of treating heart failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024511316A JP2024511316A (ja) | 2024-03-13 |
| JP2024511316A5 true JP2024511316A5 (https=) | 2025-03-14 |
Family
ID=83228302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023554809A Pending JP2024511316A (ja) | 2021-03-10 | 2022-03-09 | Ａｃｔｒｉｉ－ａｌｋ４アンタゴニスト及び心不全の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250064952A1 (https=) |
| EP (1) | EP4305052A4 (https=) |
| JP (1) | JP2024511316A (https=) |
| KR (1) | KR20230169124A (https=) |
| AU (2) | AU2022235083A1 (https=) |
| BR (1) | BR112023018283A2 (https=) |
| CA (1) | CA3211507A1 (https=) |
| MX (1) | MX2023010445A (https=) |
| WO (1) | WO2022192411A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024336884A1 (en) * | 2023-09-08 | 2026-03-26 | 35Pharma Inc. | Combination therapy with actriib receptor variants and glp-1 agonists |
| WO2025250605A1 (en) * | 2024-05-31 | 2025-12-04 | Eli Lilly And Company | Acvr2a and acvr2b rna interference agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41920B1 (fr) * | 2015-04-06 | 2021-05-31 | Acceleron Pharma Inc | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations |
| MA41919A (fr) * | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| DK3496739T3 (da) * | 2016-07-15 | 2021-05-10 | Acceleron Pharma Inc | Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension |
| CA3039573A1 (en) * | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Alk4:actriib heteromultimers and uses thereof |
| GB201620119D0 (en) * | 2016-11-29 | 2017-01-11 | Pharmafox Therapeutics Ag | Compounds |
| JP7669291B2 (ja) * | 2019-05-30 | 2025-04-28 | アクセレロン ファーマ インコーポレーテッド | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
| JP2023534127A (ja) * | 2020-06-17 | 2023-08-08 | アクセルロン ファーマ インコーポレイテッド | ＡｃｔＲＩＩ－ＡＬＫ４アンタゴニストおよび心不全を処置する方法 |
-
2022
- 2022-03-09 WO PCT/US2022/019570 patent/WO2022192411A1/en not_active Ceased
- 2022-03-09 KR KR1020237034040A patent/KR20230169124A/ko active Pending
- 2022-03-09 CA CA3211507A patent/CA3211507A1/en active Pending
- 2022-03-09 AU AU2022235083A patent/AU2022235083A1/en not_active Abandoned
- 2022-03-09 MX MX2023010445A patent/MX2023010445A/es unknown
- 2022-03-09 US US18/549,474 patent/US20250064952A1/en active Pending
- 2022-03-09 EP EP22767907.3A patent/EP4305052A4/en active Pending
- 2022-03-09 JP JP2023554809A patent/JP2024511316A/ja active Pending
- 2022-03-09 BR BR112023018283A patent/BR112023018283A2/pt unknown
-
2025
- 2025-09-11 AU AU2025230744A patent/AU2025230744A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023534127A5 (https=) | ||
| JP2024511316A5 (https=) | ||
| JP7725551B2 (ja) | アクチビンｉｉａ型受容体変異体を含む医薬組成物 | |
| ES2361917T3 (es) | Inhibidores del receptor 1 del factor de crecimiento de fibroblastos y procedimiento de tratamiento de los mismos. | |
| JP5077924B2 (ja) | 分泌された三量体受容体類似体及び生物学的活性融合タンパク質を製造するための方法及び組成物 | |
| JP2020508068A5 (https=) | ||
| JP2023181445A5 (https=) | ||
| JP2017538395A5 (https=) | ||
| JP2021511826A5 (https=) | ||
| WO2018028635A1 (zh) | 一种寨卡病毒人源单克隆抗体及其应用 | |
| US12421296B2 (en) | Activin receptor type IIB variants and uses thereof | |
| CN102686611A (zh) | 与“渐进性糖化终产物受体”结合的多肽以及包括所述多肽的组合物和方法 | |
| JP2017529059A5 (https=) | ||
| RU2014106652A (ru) | Ингибирующие моноклональные антитела против фактора xii/xiia и их применения | |
| IL273253B1 (en) | Glucagon-like peptide 1 receptor agonists and uses thereof | |
| JP2019503686A5 (https=) | ||
| RU2018128812A (ru) | Четырехвалентные антитела к psgl-1 и их применения | |
| JP2023524811A5 (https=) | ||
| CN102482350A (zh) | 作用于胰高血糖素受体的抗体及其应用 | |
| JP2024543209A5 (https=) | ||
| EP4274600A1 (en) | Compositions and methods for treating pulmonary hypertension | |
| JP2022522787A5 (https=) | ||
| JP2024544057A5 (https=) | ||
| JP2024511315A5 (https=) | ||
| JP2011526491A (ja) | インスリン融合ポリペプチド |